Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee‐For‐Service Beneficiaries
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jiayin Xue und 9 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Medicare, Obesity, Fee-for-Service Plans. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Aims
This retrospective cohort study described clinical outcomes, healthcare resource utilisation (HCRU), and costs among Medicare beneficiaries with or without obesity and stratified by cardiovascular disease (CVD) risk. Materials and Methods Using Medicare FFS claims (Jan 2016–Dec 2022), beneficiaries were indexed after 12 months of continuous enrollment and followed until death, disenrollment, or study end (≥ 12 months continuous enrollment post‐index required for HCRU and cost analyses). Outcomes were compared between beneficiaries with obesity (class ≥ 1: diagnosis/BMI ≥ 30; class ≥ 3: severe/morbid obesity/BMI ≥ 40) versus without obesity, and stratified by CVD risk (established, at‐risk and low‐risk). Time‐to‐event outcomes were assessed using Cox models, and HCRU and costs using generalised linear models and two‐part models, all adjusted for baseline covariates.
Results
A total of 21 306 251 beneficiaries were included in the study. Hazard ratios for clinical outcomes were higher among those with obesity versus without obesity, particularly for heart failure‐associated hospitalisation (class ≥ 1: 1.92; class ≥ 3: 3.40), type 2 diabetes (class ≥ 1: 1.65; class ≥ 3: 2.20) and MACE‐5 (class ≥ 1: 1.44; class ≥ 3: 2.27). Total costs (per‐patient per‐month $; cost ratio) were higher among those with obesity class ≥ 1 ($4113 vs. $2876; 1.43), and obesity class ≥ 3 ($5319 vs. $2929; 1.82), driven by high outpatient and inpatient utilisation. Results were consistent across CVD risk stratifications.
Conclusion
These findings highlight the higher risk of negative clinical outcomes and costs associated with obesity among US Medicare beneficiaries. Further research is warranted to improve treatment and prevention of obesity to mitigate risks and costs for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, USA.
- Genesis Research Group, Hoboken, USA.
- Tigermed-BDM Inc., Somerset, USA.
ORCID-Profile: Chanadda Chinthammit
Förderung
- Eli Lilly and Company
Zitieren
APA
Xue, J., Anderson, J., Huang, A., Gou, R., Sun, H., Zhao, J., Allende, C., Hua, H., Hohlbauch, A., & Chinthammit, C. (2026). Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee‐For‐Service Beneficiaries. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70999
Vancouver
Xue J, Anderson J, Huang A, Gou R, Sun H, Zhao J, et al. Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee‐For‐Service Beneficiaries. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70999
BibTeX
@article{Xue2026,
author = {Xue, Jiayin and Anderson, Jeffrey and Huang, Ahong and Gou, Ray and Sun, Haiyan and Zhao, Junhui and Allende, Catherine and Hua, Hannah and Hohlbauch, Andriana and Chinthammit, Chanadda},
title = {Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee‐For‐Service Beneficiaries},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70999}
}
EUVIMED